Antimicrobial Resistance Surveillance Market by Solution (Kits, System, Surveillance Software, Service), Application (Clinical Diagnostics, Public Health Surveillance), End User (Hospitals, Clinics, Academic, Research Institutes) & Region - Global Forecast to 2028
The global antimicrobial resistance surveillance market in terms of revenue was estimated to be worth $5.9 billion in 2023 and is poised to reach $7.7 billion by 2028, growing at a CAGR of 5.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in this market is majorly driven by factors such as the growing prevalence of infections caused by drug-resistance pathogens, innovations in diagnostic technologies and growing government initiatives to combat antimicrobial-resistance species.
Global Antimicrobial Resistance Surveillance Market Trends
To know about the assumptions considered for the study, Request for Free Sample Report
Antimicrobial Resistance Surveillance Market Dynamics
Driver: Growing prevalence of infections caused by drug-resistance pathogens
According to a published article by NCBI, within India, the incidence of VRE infections is on the rise, fluctuating between 1% and 8.7%. Our own investigation further demonstrates an escalating VRE infection rate in the bloodstream, climbing from 6.12% in 2018 to 19.2% in 2020. The growing number of epidemic outbreaks caused by drug-resistance pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), multi-drug-resistant Mycobacterium tuberculosis (MDR-TB), and carbapenem-resistant Enterobacteriaceae (CRE) gut bacteria is also propelling the demand for antimicrobial resistance surveillance solutions.
Restraint: High cost of antimicrobial resistance diagnostic systems/ kits
Antimicrobial resistance (AMR) exerts a substantial toll on economies. Beyond its human toll of mortality and disability, the protracted illnesses it causes lead to extended hospitalizations, heightened reliance on costlier pharmaceuticals, and financial hardships for affected individuals. Moreover, the pricing of AMR kits and instruments is positioned at a premium level. According to the NorthShore University Health System, the cost of reagents (at a volume of 29,200 tests per year) using automated systems is USD 165,856 per year as opposed to USD 43,508 per year using the disk diffusion method. Furthermore, the use of automated systems results in additional spending of USD 90,668 per year than that required for the semi-automated disk diffusion method.
Academic research laboratories generally cannot afford such systems as they have limited budgets. In addition, the maintenance costs and several other indirect expenses result in an overall increase in the total cost of ownership of these instruments. These factors hinder the mass adoption of antimicrobial resistance surveillance systems.
Opportunity: Growth opportunities in emerging economies
Emerging economies are expected to become a focal point for the growth of the ARS market. The Asia Pacific, Middle Eastern, and Latin American regions are relatively untapped markets for companies as compared to Europe and North America. Russia, India, China, Brazil, and South Africa are significant contributors to antibiotic adoption, accounting for 76% of the increase in antibiotic usage. The changes in antibiotic usage over the last decade have been exceptional, and this is mostly due to the advent of new illnesses. ~USD 3.3 million through the Russian Federation-funded FAO initiative was provided in 2019-20 for assisting national authorities in Armenia, Belarus, Kazakhstan, Kyrgyzstan, and Tajikistan in addressing the dangers presented by antibiotic-resistant microbes in agriculture and food systems.
Challenge: Complex Regulatory Frameworks
Among the major challenges faced by the antimicrobial resistance surveillance market is the time lag between establishing clinical breakpoints, approval of new antimicrobial agents, and the inclusion of these agents in antimicrobial susceptibility testing. Clinical breakpoints are defined as the concentration of an antibiotic that enables the interpretation of AST to define isolates as susceptible, intermediate, or resistant, thereby predicting the efficacy of an antimicrobial drug in treating a clinical disease. The FDA establishes these breakpoints when drug manufacturers submit individual new drug applications or when device manufacturers submit requests to revise the breakpoints.
Antimicrobial Resistance Surveillance Market Ecosystem Map
In 2023, the diagnostic kits segment is projected to account for the largest share of the antimicrobial resistance surveillance industry
By solutions, the global antimicrobial resistance surveillance market has been segmented into diagnostic kits, diagnostic systems, surveillance software, and services. In 2023, the diagnostic kits segment is estimated to command the largest share of the global antimicrobial resistance surveillance market. The large share of this segment can primarily be attributed to the increasing demand for rapid and accurate diagnostics for antimicrobial resistance. Diagnostic kits are used to detect the presence of antimicrobial-resistant bacteria in clinical samples, such as blood, urine, and respiratory secretions.
Clinical Diagnostics is projected to account for the largest share of the antimicrobial resistance surveillance industry in 2023
By application, the global antimicrobial resistance surveillance market has been segmented into clinical diagnostics, public health surveillance, and other applications . In 2023, the clinical diagnostics segment is expected to command the largest share of the global antimicrobial resistance surveillance market. The growth in this segment can be attributed to factors such as increasing prevalence of antimicrobial resistance, need to improve patient outcomes, used to determine the susceptibility of bacteria to different antimicrobial agents and this information is essential for healthcare providers to make informed decisions about the treatment of patients with antimicrobial-resistant infections.
By end user, hospitals and clinics accounted for the largest share of the antimicrobial resistance surveillance industry
By end users, the global antimicrobial resistance surveillance market has been segmented into hospitals & clinics, research and academic institutes, and others. In 2023, the hospitals & clinics segment is expected to command the largest share of the global antimicrobial resistance surveillance market.The large share of this segment can be attributed to the fact that because they are the primary settings where antimicrobial-resistant infections occur and they are required to conduct antimicrobial resistance surveillance.
By region, North America is projected to account for the largest share of the antimicrobial resistance surveillance industry
By region the global antimicrobial resistance surveillance segmented into—North America, Europe, Asia Pacific, Latin America, and Middle East Africa. In 2023, North American antimicrobial resistance surveillance market is expected to account for the largest share of the global antimicrobial resistance surveillance market. This can be attributed to the presence of leading market players, highest prevalence of antimicrobial resistance, and strong regulatory environment.
To know about the assumptions considered for the study, download the pdf brochure
The prominent players in this market are Luminex Corporation (US), Thermo Fisher Scientific (US), BioSpace (US), Cepheid (US), Accelerate Diagnostics, Inc. (US), Liofilchem S.r.l. (Italy), Becton, Dickinson and Company (US), Biomerieux (France), Bruker (US), Danaher (US), Merck KgaA (Germany), Bio-Rad (US), Qiagen (Germany), Abbott Laboratories (US), Roche Diagnostics (Switzerland), OpGen, Inc. (US), Wolters Kluwer N.V. (US), Lumed (US), Alifax S.r.l. (Italy), and Bioanalyse (Turkey).
Scope of the Antimicrobial Resistance Surveillance Industry:
|
Report Metric |
Details |
|
Market Revenue in 2023 |
$5.9 billion |
|
Estimated Value by 2028 |
$7.7 billion |
|
Revenue Rate |
Poised to grow at a CAGR of 5.6% |
|
Market Driver |
Growing prevalence of infections caused by drug-resistance pathogens |
|
Market Opportunity |
Growth opportunities in emerging economies |
The study categories the antimicrobial resistance surveillance Market to forecast revenue and analyze trends in each of the following submarkets:
By Solution
- Diagnostic kits
- Diagnostic systems
- Surveillance software
- Services
By Application
- Clinical Diagnostics
- Public Health Surveillance
- Other Applications
By End User
- Hospitals & Clinics
- Research & Academic Institutes
- Others
By Region
-
North America
- US
- Canada
-
Europe
- France
- Spain
- UK
- Italy
- Germany
- Rest of Europe
-
Asia Pacific
- China
- India
- Japan
- Rest of APAC
-
Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global antimicrobial resistance surveillance market?
The global antimicrobial resistance surveillance market boasts a total revenue value of $7.7 billion by 2028.
What is the estimated growth rate (CAGR) of the global antimicrobial resistance surveillance market?
The global antimicrobial resistance surveillance market has an estimated compound annual growth rate (CAGR) of 5.6% and a revenue size in the region of $5.9 billion in 2023.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
This research study involved the use of comprehensive secondary sources; directories and databases such as D&B, Bloomberg Business, and Factiva; and white papers, annual reports, and companies’ house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of the antimicrobial resistance surveillance market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, technology perspectives, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side and demand side are detailed below. Industry experts such as CEOs, presidents, vice presidents, directors, marketing directors, marketing managers, and related executives from various key companies and organizations in the antimicrobial resistance surveillance industry were interviewed to obtain and verify both the qualitative and quantitative aspects of this research study. A robust primary research methodology has been adopted to validate the contents of the report and fill in the gaps.
A breakdown of the primary respondents is provided below:
*Others include sales managers, marketing managers, and product managers.
Note: Tiers are defined based on a company’s total revenue, as of 2022: Tier 1 = >USD 5 billion, Tier 2 = USD 1 billion to USD 5 billion, and Tier 3 = <USD 1 billion.
To know about the assumptions considered for the study, download the pdf brochure
|
COMPANY NAME |
DESIGNATION |
|
Danaher |
Assistant Manager Sales |
|
Luminex Corporation |
Assistant Project Manager |
|
Qiagen |
Business Development Manager |
Market Size Estimation
The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (revenue share analysis) primary interviews, and top-down approach (assessment of Individual shares of each solution, application, and end-user segment).
Antimicrobial Resistance Surveillance Market Size: Revenue Share Analysis
Antimicrobial Market Size: Bottom up Approach
- For estimating the size of the global Antimicrobial resistance surveillance market, the country-level market revenues were obtained from secondary sources and through extensive primary interviews.
- Country-level markets for the US and Canada were added to arrive at the market size for North America. Similarly, country-level markets for Germany, France, the UK, Spain, Italy, and the Rest of Europe were added to arrive at the market size for Europe, and the market sizes of Japan, China, India, and the Rest of Asia Pacific were added to arrive at the market size of the Asia Pacific.
- The markets for North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa were added to arrive at the global market.
- The total market derived through the bottom-up approach was again validated through secondary sources and primary interviews.
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation, and market breakdown procedures were employed, wherever applicable.
To know about the assumptions considered for the study, Request for Free Sample Report
Market Definition
Antimicrobial resistance (AMR) surveillance is a systematic process of monitoring and tracking the ability of microorganisms (such as bacteria, viruses, fungi) to resist the effects of antimicrobial drugs, including antibiotics, antivirals, and antifungal medications.
Key Stakeholders
- Distributors, Suppliers, and Commercial Service Providers
- Healthcare Service Providers
- Manufacturers of Pharmaceutical Products
- Clinical Research Organizations (CROs)
- Clinical Testing Laboratories
- Blood Culture Media Manufacturers
- Food & Beverage Manufacturing Companies
- Environmental Monitoring Committees
- Manufacturers of Environmental Monitoring Products
- National & Regional Pollution Control Boards and Organizations
- Research Laboratories and Academic Institutes
- Market Research and Consulting Firms
Objectives of the Study
- To define, describe, segment, and forecast the antimicrobial resistance surveillance market by solution, application, end user, and region
- To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall antimicrobial resistance surveillance market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To estimate and forecast the size of the antimicrobial resistance surveillance market in five main regions (along with their respective key countries), namely, North America, Europe, the Asia Pacific, Latin America, and Middle East Africa.
- To profile the key players and analyze their market shares and core competencies3
- To track and analyze competitive developments such as product launches, agreements, partnership, and acquisitions in the global antimicrobial resistance surveillance market
- To benchmark players within the antimicrobial resistance surveillance market using the competitive leadership mapping framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolio of each company
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Growth opportunities and latent adjacency in Antimicrobial Resistance Surveillance Market